Gene expression profiling reveals new aspects of PIK3CA mutation in eralpha-positive breast cancer: Major implication of the Wnt signaling pathway

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Cizkova, Magdalena ^a,b   Cizeron Clairac, Géraldine ^a   Vacher, Sophie ^a   Susini, Aurélie ^a   Andrieu, Catherine ^a   Lidereau, Rosette ^a   Bièche, Ivan ^a  

^a INSTITUT CURIE   (France)

^b PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CYTOCHROME P450; CYTOCHROME P450 CYP4Z1; CYTOCHROME P450 CYP4Z2P; ESTROGEN RECEPTOR ALPHA; IRON BINDING PROTEIN; LACTOFERRIN; OSTEOPROTEGERIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN LIMCH1; PROTEIN NRIP3; PROTEIN PIK3CA; PROTEIN SEC14L2; PROTEIN SLC40A1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR 7 LIKE 2; TRANSCRIPTION FACTOR MSX2; UNCLASSIFIED DRUG; WNT PROTEIN; WNT5A PROTEIN; PIK3CA PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; BREAST TUMOR; CATALYSIS; DNA MICROARRAY; ENZYME ACTIVE SITE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION;

BREAST NEOPLASMS; CATALYSIS; CATALYTIC DOMAIN; DNA MUTATIONAL ANALYSIS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHATIDYLINOSITOL 3-KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 78651233471     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015647     Document Type: Article

References (48)

1. Zhao L, Vogt PK (2008) Class I PI3K in oncogenic cellular transformation. Oncogene 27: 5486-5496.
2. Dillon RL, White DE, Muller WJ (2007) The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 26: 1338-1345.
3. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554.
4. Karakas B, Bachman KE, Park BH (2006) Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 94: 455-459.
5. Zhao JJ, Liu Z, Wang L, Shin E, Loda MF, et al. (2005) The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci U S A 102: 18443-18448.
6. Bader AG, Kang S, Vogt PK (2006) Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci U S A 103: 1475-1479.
7. Saal LH, Holm K, Maurer M, Memeo L, Su T, et al. (2005) PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65: 2554-2559.
8. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, et al. (2008) An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68: 6084-6091.
9. Tibshirani R, Hastie T, Narasimhan B, Chu G (2002) Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 99: 6567-6572.
10. Bieche I, Onody P, Laurendeau I, Olivi M, Vidaud D, et al. (1999) Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin Chem 45: 1148-1156.
11. Matthews BW (1975) Comparison of the predicted and observed secondary structure of T4 phage lysozyme. Biochim Biophys Acta 405: 442-451.
12. Gee JM, Robertson JF, Ellis IO, Nicholson RI, Hurst HC (1999) Immunohistochemical analysis reveals a tumour suppressor-like role for the transcription factor AP-2 in invasive breast cancer. J Pathol 189: 514-520.
13. Johnykutty S, Tang P, Zhao H, Hicks DG, Yeh S, et al. (2009) Dual expression of alpha-tocopherol-associated protein and estrogen receptor in normal/benign human breast luminal cells and the downregulation of alpha-tocopherolassociated protein in estrogen-receptor-positive breast carcinomas. Mod Pathol 22: 770-775.
14. Shan L, Yu M, Qiu C, Snyderwine EG (2003) Id4 regulates mammary epithelial cell growth and differentiation and is overexpressed in rat mammary gland carcinomas. Am J Pathol 163: 2495-2502.
15. Tang W, Dodge M, Gundapaneni D, Michnoff C, Roth M, et al. (2008) A genome-wide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. Proc Natl Acad Sci U S A 105: 9697-9702.
16. Satoh K, Ginsburg E, Vonderhaar BK (2004) Msx-1 and Msx-2 in mammary gland development. J Mammary Gland Biol Neoplasia 9: 195-205.
17. Cheng SL, Shao JS, Cai J, Sierra OL, Towler DA (2008) Msx2 exerts bone anabolism via canonical Wnt signaling. J Biol Chem 283: 20505-20522.
18. Riggins RB, Lan JP-J, Klimach U, Zwart A, Cavalli LR, et al. (2008) ERR Mediates Tamoxifen Resistance in Novel Models of Invasive Lobular Breast Cancer. Cancer Res 68: 8908-8917.
19. Andre F, Mazouni C, Liedtke C, Kau SW, Frye D, et al. (2008) HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. Breast Cancer Res Treat 108: 183-190.
20. Reya T, Clevers H (2005) Wnt signalling in stem cells and cancer. Nature 434: 843-850.
21. Nteliopoulos G, Marley SB, Gordon MY (2009) Influence of PI-3K/Akt pathway on Wnt signalling in regulating myeloid progenitor cell proliferation. Evidence for a role of autocrine/paracrine Wnt regulation. Br J Haematol 146: 637-651.
22. Veeman MT, Axelrod JD, Moon RT (2003) A second canon. Functions and mechanisms of beta-catenin-independent Wnt pathway. Dev Cell 5: 367-77.
23. Leris AC, Roberts TR, Jiang WG, Newbold RF, Mokbel K (2005) WNT5A expression in human breast cancer. Anticancer Res 25: 731-734.
24. Ford CE, Ekström EJ, Howlin J, Andersson T (2009) The WNT-5a derived peptide, Foxy-5, possesses dual properties that impair progression of ERalpha negative breast cancer. Cell Cycle 8: 1838-42.
25. Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, et al. (2010) Proc Natl Acad Sci U S A 107: 10208-13.
26. Katoh M (2005) WNT/PCP signaling pathway and human cancer. Oncol Rep 14: 1583-1588.
27. Willert J, Epping M, Pollack JR, Brown PO, Nusse R (2002) A transcriptional response to Wnt protein in human embryonic carcinoma cells. BMC Dev Biol 2: 8.
28. Krishnan V, Bryant HU, Macdougald OA (2006) Regulation of bone mass by Wnt signaling. J Clin Invest 116: 1202-1209.
29. Bu G, Lu W, Liu CC, Selander K, Yoneda T, et al. (2008) Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: implication for breast cancer osteolytic bone metastases. Int J Cancer 123: 1034-1042.
30. Malanchi I, Huelsken J (2009) Cancer stem cells: never Wnt away from the niche. Curr Opin Oncol 21: 41-46.
31. Wang Y (2009) Wnt/Planar cell polarity signaling: A new paradigm for cancer therapy. Mol Cancer Ther 8: 2103-2109.
32. Yook JI, Li XY, Ota I, Hu C, Kim HS, et al. (2006) A Wnt-Axin2-GSK3beta cascade regulates Snail1 activity in breast cancer cells. Nat Cell Biol 8: 1398-1406.
33. DiMeo TA, Anderson K, Phadke P, Fan C, Perou CM, et al. (2009) A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res 69: 5364-5373.
34. Baryawno N, Sveinbjörnsson B, Eksborg S, Chen CS, Kogner P, et al. (2010) Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth. Cancer Res 70: 266-276.
35. Samuels Y, Diaz LA, Jr., Schmidt-Kittler O, Cummins JM, Delong L, et al. (2005) Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7: 561-573.
36. Carnero A (2009) Novel inhibitors of the PI3K family. Expert Opin Investig Drugs 18: 1265-1277.
37. Weng LP, Smith WM, Brown JL, Eng C (2001) PTEN inhibits insulinstimulated MEK/MAPK activation and cell growth by blocking IRS-1 phosphorylation and IRS-1/Grb-2/Sos complex formation in a breast cancer model. Hum Mol Genet 10: 605-616.
38. Barker N, Clevers H (2006) Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 5: 997-1014.
39. Abba MC, Hu Y, Sun H, Drake JA, Gaddis S, et al. (2005) Gene expression signature of estrogen receptor alpha status in breast cancer. BMC Genomics 6: 37.
40. Benaïssa M, Peyrat JP, Hornez L, Mariller C, Mazurier J, et al. (2005) Expression and prognostic value of lactoferrin mRNA isoforms in human breast cancer. Int J Cancer 114: 299-306.
41. Rieger MA, Ebner R, Bell DR, Kiessling A, Rohayem J, et al. (2004) Identification of a novel mammary-restricted cytochrome P450, CYP4Z1, with overexpression in breast carcinoma. Cancer Res 64: 2357-2364.
42. Esseghir S, Kennedy A, Seedhar P, Nerurkar A, Poulsom R, et al. (2007) Identification of NTN4, TRA1, and STC2 as prognostic markers in breast cancer in a screen for signal sequence encoding proteins. Clin Cancer Res 13: 3164-3173.
43. Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL, et al. (2005) Microtubuleassociated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A 102: 8315-8320.
44. Nakshatri H, Mendonca MS, Bhat-Nakshatri P, Patel NM, Goulet RJ, Jr., et al. (2000) The orphan receptor COUP-TFII regulates G2/M progression of breast cancer cells by modulating the expression/activity of p21(WAF1/CIP1), cyclin D1, and cdk2. Biochem Biophys Res Commun 270: 1144-1153.
45. Navab R, Gonzalez-Santos JM, Johnston MR, Liu J, Brodt P, et al. (2004) Expression of chicken ovalbumin upstream promoter-transcription factor II enhances invasiveness of human lung carcinoma cells. Cancer Res 64: 5097-5105.
46. Maxwell GL, Chandramouli GV, Dainty L, Litzi TJ, Berchuck A, et al. (2005) Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer. Clin Cancer Res 11: 4056-4066.
47. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, et al. (2006) Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66: 2815-2825.
48. Wu F, Ivanov I, Xu R, Safe S (2009) Role of SP transcription factors in hormone-dependent modulation of genes in MCF-7 breast cancer cells: microarray and RNA interference studies. J Mol Endocrinol 42: 19-33.